DermTech, Inc.

OTCPK:DMTK.Q 株式レポート

時価総額：US$35.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

DermTech バランスシートの健全性

財務の健全性 基準チェック /36

DermTechの総株主資本は$40.0M 、総負債は$0.0で、負債比率は0%となります。総資産と総負債はそれぞれ$103.0Mと$63.0Mです。

主要情報

0%

負債資本比率

US$0

負債

インタレスト・カバレッジ・レシオn/a
現金US$38.98m
エクイティUS$39.99m
負債合計US$62.98m
総資産US$102.97m

財務の健全性に関する最新情報

分析記事 • Mar 02

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Recent updates

分析記事 • May 21

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 44% in the last...
分析記事 • Mar 02

We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
分析記事 • Mar 02

Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 28% in the last...
分析記事 • Dec 28

Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price

You may think that with a price-to-sales (or "P/S") ratio of 4.5x DermTech, Inc. ( NASDAQ:DMTK ) is definitely a stock...
分析記事 • Sep 18

Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Jun 14

Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • May 10

Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023

One thing we could say about the analysts on DermTech, Inc. ( NASDAQ:DMTK ) - they aren't optimistic, having just made...
分析記事 • May 06

DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%

To the annoyance of some shareholders, DermTech, Inc. ( NASDAQ:DMTK ) shares are down a considerable 37% in the last...
分析記事 • Jan 16

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Nov 08

Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)

The latest analyst coverage could presage a bad day for DermTech, Inc. ( NASDAQ:DMTK ), with the analysts making...
分析記事 • Oct 11

Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 11

DermTech grants stock options

DermTech (NASDAQ:DMTK) granted one new, non-executive employee non-qualified stock options to buy ~38.78K common shares. The stock options, which have an exercise price of $4 per share, were granted under Inducement Equity Incentive Plan, the company said in an Oct. 10 press release.
Seeking Alpha • Sep 01

Diving Into DermTech

Summary Today, we take our first look at DermTech, Inc., a small molecular testing concern. The company is seeing some sales traction and the stock sells for less than cash value, but DermTech's cash burn rate is more than concerning. A full investment analysis of DermTech follows in the paragraphs below. Come friends, it's not too late to seek a newer world.”― Alfred Lord Tennyson Today, we put the spotlight on a small diagnostic firm called DermTech, Inc. (DMTK). This company has what it is a potential "best of breed" and non-invasive way to test for melanoma. Its core product is seeing some sales traction and the company currently has a lot of cash on the balance sheet. However, cash burn is a major concern around DermTech. An analysis follows below. Seeking Alpha Company Overview: DermTech, Inc. is a molecular testing concern based out of La Jolla, California. The company develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the U.S. The shares currently trade around $5.50 a share and sport an approximate market capitalization of $170 million. November 2021 Company Presentation The company's non-invasive tests to diagnose skin conditions that are more effective than traditional biopsy-based diagnostic tests. The company's main test right now is called the DermTech Smart Sticker. This replaces a scalpel to remove the skin cells off the surface of a mole. The DermTech Smart Sticker provides an accurate, non-invasive test to detect melanoma. November Company Presentation Second Quarter Results: On August 8th, the company posted second quarter numbers. DermTech had a GAAP loss of 99 cents a share, slightly better than the consensus. Revenues rose nearly 36% on a year-over-year. However, revenues were only $4.23 million, and that was somewhat under expectations. The company's net loss for the quarter widened to $29.6 million compared with a loss of $17.1 million in 2Q2021. Assay revenue increased by over 40% to $4.15 million while contract revenue declined some 60% to just to $86,000. Billable sample volume grew 56% to 18,320 compared to the same period a year ago. The company also saw a 67% increase in unique ordering clinicians to approximately 2,390. Thanks to continued acceptance, DermTech Smart Sticker is now available to approximately 91 million covered lives. This breaks down as nearly 68 million for Medicare and Medicare Advantage and 23 million for commercial payers, which largely comes today from the Blue Shields of California, Illinois and Texas. The stock got hit when management took down their full year assay revenue estimate to $16 million to $19 million from $22 million to $26 million previously. The company has streamlined the laboratory processes, which reduced the per unit cost of the DermTech Smart Sticker by 28% sequentially to $177 per, but the product is also seeing a lower average selling price, or ASP, which is a key reason for the downward sales guidance revision. ASP was under pressure due to Medicare billing code edits, which are expected to be improved in the coming quarters. The company is pushing the launch of their direct-to-consumer offering "Luminate" that assesses skin cancer risk to the first half of 2023 to conserve costs. Analyst Commentary & Balance Sheet: Since second quarter results came out, four analyst firms including BTIG and Oppenheimer have reiterated Buy ratings. However, all four analyst firms significantly cut their price targets on DermTech. Price targets now proffered range from $14 to $24 a share. Prior to price target revisions, price targets from these four analyst firms was in the $19 to $48 range. Approximately one out of eight shares are currently held short. Numerous insiders have been frequent, but mostly small, sellers of the stock in 2022. They have sold approximately $500,000 worth of equity in aggregate so far this year. The last insider purchases of DMTK were in February of 2020. The company ended the second quarter of this year with just north of $175 million worth of cash and marketable securities on its balance sheet. Leadership believes this is sufficient capital to fund its current operating plan through the first quarter of 2024 Verdict: The current analyst consensus has the company losing nearly four bucks a share in FY2022 even as revenues advance over 50% to some $18 million. Next year, revenue growth is expected to accelerate with the company doing some $30 in sales in FY2023. However, losses are expected to only come down around 10%.
分析記事 • Aug 10

Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80

One of the biggest stories of last week was how DermTech, Inc. ( NASDAQ:DMTK ) shares plunged 33% in the week since its...
Seeking Alpha • Jun 13

DermTech: Approaching An All Or Nothing Moment

DermTech (DMTK) has transformative solutions that are more effective and accurate than traditional biopsy-based diagnostic approaches for detecting Skin Cancer. Commercialization of its proprietary SmartSticker solution has been slow, despite recent significant investments in the company’s salesforce. Although the company’s solutions have enormous potential and could drive the stock price significantly higher if successfully commercialized, recent management guidance for the next 12 months was soft. The future outcome for DMTK may be binary - either massive success driven by mass product adoption or a slow fade to oblivion based on failed commercialization.
分析記事 • Jun 04

We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Mar 31

DermTech - Taking A Second Look At The Growth Thesis

DMTK’s SmartSticker solution is proprietary and has been shown to be more effective and accurate than traditional biopsy-based diagnostic approaches, but the company must further commercialize this offering. DMTK has made significant sales, marketing and infrastructure investments over the past 6 months, which should drive 2022 to be a record financial year for the company. Investors should approach this opportunity with caution while collecting more data on DMTK’s ability to grow sales. The longer-term opportunity remains if DMTK can execute on its core growth strategies.
Seeking Alpha • Dec 23

DermTech: Adoption Headwinds And Earnings Misses

DMTK has a skin cancer diagnostics test in the market. The company has repeatedly missed earnings, and this time, they also lowered guidance. This sort of steady depletion of shareholder value does not look good for future investments.

財務状況分析

短期負債: DMTK.Qの 短期資産 ( $44.2M ) が 短期負債 ( $12.5M ) を超えています。

長期負債: DMTK.Qの短期資産 ( $44.2M ) は 長期負債 ( $50.5M ) をカバーしていません。

デット・ツー・エクイティの歴史と分析

負債レベル: DMTK.Qは負債がありません。

負債の削減: DMTK.Qは現在負債はありませんが、その期間のデータがないため、5 年前と比較することはできません。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: 現在のフリーキャッシュフローに基づいて、 DMTK.Qに十分なキャッシュランウェイがあるかどうかを判断するにはデータが不十分です。

キャッシュランウェイの予測: DMTK.Qの フリー キャッシュ フロー が過去のレートに基づいて増加または減少し続ける場合、十分な キャッシュ ランウェイ があるかどうかを判断するためのデータが不十分です。

健全な企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2025/07/23 22:58
終値2025/07/23 00:00
収益2024/03/31
年間収益2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

DermTech, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10

アナリスト機関
Sally YanchusBrookline Capital Markets
Mark MassaroBTIG
Alexander NowakCraig-Hallum Capital Group LLC